PBR28
Lewy Body Dementia
Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Columbia University
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lewy Body Dementia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| PBR28 (this asset) | Columbia University | P2 | B · 57 |
| Memantine | Zealand University Hospital | P4 | BBB |
| 6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS) | Virginia Commonwealth University | P4 | BB |
| Dapagliflozin | Mayo Clinic | P4 | BB |
| Armodafinil | NYU Langone Health | P4 | BB |
| Intepirdine | Axovant Sciences Ltd. | P2/3 | BB |
| Sitagliptin | Mayo Clinic | P4 | BB |
| Irsenontrine | Eisai Inc. | P2 | BB |
| Zoledronate | California Pacific Medical Center Research Institute | P4 | BB |
+41 more in the Lewy Body Dementia cohort
Other indications for PBR28
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Multiple Sclerosis | — | P4 | B · 63 |
| Alzheimer Disease | — | P2 | B · 62 |
| Traumatic Brain Injury | — | P1/2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. PBR28 in Lewy Body Dementia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/pbr28-lewy-body-dementia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →